NATIONAL: FCC OKs waiver to trace anonymous threats to Jewish centers

The Jewish Community Center is seen in Tarrytown, N.Y., Tuesday, Feb. 28, 2017. The latest in a wave of bomb threat hoaxes called into more than 20 Jewish community centers and schools across the country has again put administrators in the position of having to decide whether a threatening message on the other end of a phone line was enough to evacuate.

Sanofi and Regeneron Announce Presentation of Positive Data from…

Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Paris, France and Tarrytown, N.Y. - March 4, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today presented detailed results from the one-year Phase 3 CHRONOS study, which showed that patients receiving the investigational drug DupixentA with topical corticosteroids achieved significantly improved measures of overall disease severity compared to TCS alone in adults with uncontrolled moderate-to-severe atopic dermatitis .